Van den Bossche started his career as a biotech analyst at Petercam. There he was involved for more than 12 years in numerous public and private transactions of Belgian and Dutch biotech companies, such as ThromboGenics, Tigenix, UCB, AMT (Uniqure), IBA, MDxHealth. Prior to joining Andera Partners, he worked for 7 years as a partner at Fund+, a Belgium-based fund investing in the life sciences sector.

Andera Life Sciences partners (Sofia Ioannidou, Gilles Nobécourt, Raphaël Wisniewski and Olivier Litzka) comment: “We are delighted to reinforce the Andera Life Sciences team with an experienced investor like Jan. His arrival will allow us to accelerate the roll-out of our new BioDiscovery 6 fund and to further support our portfolio companies.

The Andera Life Sciences team is now composed of 15 professionals including 5 partners and 3 venture partners. Active since 2000, the team has raised over €1.1 billion through its BioDiscovery family of funds and is currently investing from its new BioDiscovery 6 fund. Since inception, the BioDiscovery funds have invested in more than 75 European and U.S. biotech and medtech companies.